Summarized by Masters of Longevity from Longevity Technology.
Discussion of peptide medicine’s rapid consumer adoption and the need to close gray-market gaps through better supply chains, testing, and clinical follow-up.
Key Takeaways
- Demand for peptide therapies is outpacing clinical evidence and regulatory infrastructure, increasing gray-market availability.
- Celia RX is building an integrated model covering sourcing, batch testing, clinical assessment, prescribing, and longitudinal monitoring.
- Experts propose specialized AI tools to support clinicians with evidence navigation and patient monitoring without replacing medical judgment.
